Gregory L. Weaver net worth and biography

Gregory Weaver Biography and Net Worth

Director of Atossa Genetics

Gregory L. Weaver serves as Independent Director of the Company. Mr. Weaver served as Chief Financial Officer of Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) a publicly traded biotech company from September 2017 to March 2020. Mr. Weaver previously served as the Chief Financial Officer from October 2015 to August 2017 with ProMetic Life Sciences, and from January to October 2015 with Oryzon Genomics. Mr. Weaver received his undergraduate degree in finance from Trinity University and his MBA from Boston College. Mr. Weaver has been selected to serve on the Company’s Board of Directors because of his qualifications as a business executive and audit committee financial expert, and his current and prior experience as a Chief Financial Officer, director and committee member of public companies. From 2014 to January 2020, Mr. Weaver served on the board of directors of Egalet Corp., a publicly traded biotech company, and from September 2014 to January 2015 on the board of directors of Oryzon Genomics, a publicly traded biotech company.

What is Gregory L. Weaver's net worth?: The estimated net worth of Gregory L. Weaver is at least $7.60 thousand as of March 13th, 2025. Mr. Weaver owns 10,000 shares of Atossa Genetics stock worth more than $7,595 as of December 5th. This net worth evaluation does not reflect any other assets that Mr. Weaver may own. Learn More about Gregory L. Weaver's net worth.
How do I contact Gregory L. Weaver?: The corporate mailing address for Mr. Weaver and other Atossa Genetics executives is 107 SPRING STREET, SEATTLE WA, 98104. Atossa Genetics can also be reached via phone at (206) 588-0256 and via email at [email protected]. Learn More on Gregory L. Weaver's contact information.
Has Gregory L. Weaver been buying or selling shares of Atossa Genetics?: Gregory L. Weaver has not been actively trading shares of Atossa Genetics in the last ninety days. Most recently, Gregory L. Weaver sold 107,497 shares of the business's stock in a transaction on Friday, July 2nd. The shares were sold at an average price of $5.58, for a transaction totalling $599,833.26. Learn More on Gregory L. Weaver's trading history.
Are insiders buying or selling shares of Atossa Genetics?: In the last twelve months, Atossa Genetics insiders bought shares 2 times. They purchased a total of 21,239 shares worth more than $16,890.32. The most recent insider tranaction occured on May, 21st when CEO Steven C Quay bought 11,239 shares worth more than $9,890.32. Insiders at Atossa Genetics own 7.6% of the company. Learn More about insider trades at Atossa Genetics.
Information on this page was last updated on 5/21/2025.

Gregory L. Weaver Insider Trading History at Atossa Genetics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/2/2021	Sell	107,497	$5.58	$599,833.26
11/21/2013	Buy	10,000	$2.58	$25,800.00

Gregory L. Weaver Buying and Selling Activity at Atossa Genetics

Atossa Genetics Company Overview

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Today's Range

Now: $0.76

$0.73

$0.77

50 Day Range

MA: $0.88

$0.70

$1.18

2 Week Range

Now: $0.76

$0.55

$1.30

Volume

702,218 shs

Average Volume

551,323 shs

Market Capitalization

$98.10 million

P/E Ratio

N/A

Dividend Yield